Erratum to: n-3 Polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism (Molecular Psychiatry, (2007), 12, 1, (36-46), 10.1038/sj.mp.4001888);n-3 Polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism

Molecular Psychiatry

Volumn 12, Issue 1, 2007, Pages 36-46

  Rao, J S ^a   Ertley, R N ^a   Lee, H J ^a   DeMar Jr , J C ^a   Arnold, J T ^b   Rapoport, S I ^a   Bazinet, R P ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b National Institutes of Health   (United States)

Author keywords

BDNF; Bipolar disorder; Brain; Docosahexaenoic acid; MAPK; PKA; Rat

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOCOSAHEXAENOIC ACID; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; OMEGA 3 FATTY ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN CORTEX; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; FRONTAL CORTEX; IN VITRO STUDY; MALE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STATISTICAL SIGNIFICANCE; TRANSCRIPTION INITIATION;

EID: 33845775752     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2017.199     Document Type: Erratum

References (90)

1. Diau GY, Hsieh AT, Sarkadi-Nagy EA, Wijendran V, Nathanielsz PW, Brenna JT. The influence of long chain polyunsaturate supplementation on docosahexaenoic acid and arachidonic acid in baboon neonate central nervous system. BMC Med 2005; 3: 11.
2. Vaidyanathan VV, Rao KV, Sastry PS. Regulation of diacylglycerol kinase in rat brain membranes by docosahexaenoic acid. Neurosci Lett 1994; 179: 171-174.
3. Salem Jr N, Litman B, Kim HY, Gawrisch K. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 2001; 36: 945-959.
4. Innis SM. Perinatal biochemistry and physiology of long-chain polyunsaturated fatty acids. J Pediatr 2003; 143: S1-S8.
5. Salem Jr N, Moriguchi T, Greiner RS, McBride K, Ahmad A, Catalan JN et al. Alterations in brain function after loss of docosahexaenoate due to dietary restriction of n-3 fatty acids. J Mol Neurosci 2001; 16: 299-307; discussion 317-221.
6. Chen C, Bazan NG. Lipid signaling: sleep, synaptic plasticity, and neuroprotection. Prostaglandins Other Lipid Mediat 2005; 77: 65-76.
7. Sprecher H. Metabolism of highly unsaturated n-3 and n-6 fatty acids. Biochim Biophys Acta 2000; 1486: 219-231.
8. Sastry PS. Lipids of nervous tissue: composition and metabolism. Prog Lipid Res 1985; 24: 69-176.
9. Noaghiul S, Hibbeln JR. Cross-national comparisons of seafood consumption and rates of bipolar disorders. Am J Psychiatry 2003; 160: 2222-2227.
10. Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 2003; 121: 109-122.
11. Chiu CC, Huang SY, Su KP, Lu ML, Huang MC, Chen CC et al. Polyunsaturated fatty acid deficit in patients with bipolar mania. Eur Neuropsychopharmacol 2003; 13: 99-103.
12. McNamara RK, Hahn CG, Richtand NM, Jandacek RJ, Tso P. Reductions in the principle brain omega-3 fatty acid, docosahexaenoic acid, in portmortem prefrontal cortex of patients with schizophrenia, bipolar disorder, and major depressive disorder, but not multiple sclerosis or Alzheimer's disease. Biol Psychiatry 2006; 59S: 30S, Abstract #96.
13. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999; 56: 407-412.
14. Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry 2006; 188: 46-50.
15. Demar Jr JC, Ma K, Bell JM, Igarashi M, Greenstein D, Rapoport SI. One generation of n-3 polyunsaturated fatty acid deprivation increases depression and aggression test scores in rats. J Lipid Res 2006; 47: 172-180.
16. D'Sa C, Duman RS. Antidepressants and neuroplasticity. Bipolar Disord 2002; 4: 183-194.
17. Duman RS. Pathophysiology of depression: the concept of synaptic plasticity. Eur Psychiatry 2002; 17(Suppl 3): 306-310.
18. Manji HK, Moore GJ, Rajkowska G, Chen G. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000; 5: 578-593.
19. Maitre M. Memory and synaptic plasticity. Ann Biol Clin (Paris) 1996; 54: 49-66.
20. Chuang DM. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases? Crit Rev Neurobiol 2004; 16: 83-90.
21. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996; 16: 2365-2372.
22. Ghosh A, Carnahan J, Greenberg ME. Requirement for BDNF in activity-dependent survival of cortical neurons. Science 1994; 263: 1618-1623.
23. Finkbeiner S, Tavazoie SF, Maloratsky A, Jacobs KM, Harris KM, Greenberg ME. CREB: a major mediator of neuronal neurotrophin responses. Neuron 1997; 19: 1031-1047.
24. Montminy MR, Bilezikjian LM. Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene. Nature 1987; 328: 175-178.
25. Yamamoto KK, Gonzalez GA, Biggs III WH, Montminy MR. Phosphorylation- induced binding and transcriptional efficacy of nuclear factor CREB. Nature 1988; 334: 494-498.
26. Gonzalez GA, Montminy MR. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 1989; 59: 675-680.
27. Blois JT, Mataraza JM, Mecklenbrauker I, Tarakhovsky A, Chiles TC. B cell receptor-induced cAMP-response element-binding protein activation in B lymphocytes requires novel protein kinase Cdelta. J Biol Chem 2004; 279: 30123-30132.
28. Xing J, Kornhauser JM, Xia Z, Thiele EA, Greenberg ME. Nerve growth factor activates extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways to stimulate CREB serine 133 phosphorylation. Mol Cell Biol 1998; 18: 1946-1955.
29. Deak M, Clifton AD, Lucocq LM, Alessi DR. Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J 1998; 17: 4426-4441.
30. Tiraboschi E, Tardito D, Kasahara J, Moraschi S, Pruneri P, Gennarelli M et al. Selective phosphorylation of nuclear CREB by fluoxetine is linked to activation of CaM kinase IV and MAP kinase cascades. Neuropsychopharmacology 2004; 29: 1831-1840.
31. Cunha AB, Frey BN, Andreazza AC, Goi JD, Rosa AR, Goncalves CA et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 2006; 398: 215-219.
32. Knable MB, Barci BM, Webster MJ, Meador-Woodruff J, Torrey EF. Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. Mol Psychiatry 2004; 9: 609-620, 544.
33. Laifenfeld D, Karry R, Klein E, Ben-Shachar D. Alterations in cell adhesion molecule L1 and functionally related genes in major depression: a postmortem study. Biol Psychiatry 2005; 57: 716-725.
34. Lohoff FW, Sander T, Ferraro TN, Dahl JP, Gallinat J, Berrettini WH. Confirmation of association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and bipolar I disorder. Am J Med Genet B Neuropsychiatr Genet 2005; 139: 51-53.
35. Neves-Pereira M, Mundo E, Muglia P, King N, Macciardi F, Kennedy JL. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am J Hum Genet 2002; 71: 651-655.
36. Sklar P, Gabriel SB, McInnis MG, Bennett P, Lim YM, Tsan G et al. Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neutrophic factor. Mol Psychiatry 2002; 7: 579-593.
37. Okada T, Hashimoto R, Numakawa T, Iijima Y, Kosuga A, Tatsumi M et al. A complex polymorphic region in the brain-derived neurotrophic factor (BDNF) gene confers susceptibility to bipolar disorder and affects transcriptional activity. Mol Psychiatry 2006; 11: 695-703.
38. Einat H, Yuan P, Gould TD, Li J, Du J, Zhang L et al. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 2003; 23: 7311-7316.
39. Frey BN, Andreazza AC, Cereser KM, Martins MR, Valvassori SS, Reus GZ et al. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci 2006; 79: 281-286.
40. Hashimoto K, Shimizu E, Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev 2004; 45: 104-114.
41. Yatham LN. Translating knowledge of genetics and pharmacology into improving everyday practice. Bipolar Disord 2005; 7(Suppl 4): 13-20.
42. Zarate Jr CA, Singh J, Manji HK. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry 2006; 59: 1006-1020.
43. Wu A, Ying Z, Gomez-Pinilla F. Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J Neurotrauma 2004; 21: 1457-1467.
44. Soares JC, Kochunov P, Monkul ES, Nicoletti MA, Brambilla P, Sassi RB et al. Structural brain changes in bipolar disorder using deformation field morphometry. Neuroreport 2005; 16: 541-544.
45. Lopez-Larson MP, DelBello MP, Zimmerman ME, Schwiers ML, Strakowski SM. Regional prefrontal gray and white matter abnormalities in bipolar disorder. Biol Psychiatry 2002; 52: 93-100.
46. Lyoo IK, Kim MJ, Stoll AL, Demopulos CM, Parow AM, Dager SR et al. Frontal lobe gray matter density decreases in bipolar I disorder. Biol Psychiatry 2004; 55: 648-651.
47. Rajkowska G. Cell pathology in bipolar disorder. Bipolar Disord 2002; 4: 105-116.
48. DeMar Jr JC, Ma K, Bell JM, Rapoport SI. Half-lives of docosahexaenoic acid in rat brain phospholipids are prolonged by 15 weeks of nutritional deprivation of n-3 polyunsaturated fatty acids. J Neurochem 2004; 91: 1125-1137.
49. Moriguchi T, Loewke J, Garrison M, Catalan JN, Salem Jr N. Reversal of docosahexaenoic acid deficiency in the rat brain, retina, liver, and serum. J Lipid Res 2001; 42: 419-427.
50. Calderon F, Kim HY. Docosahexaenoic acid promotes neurite growth in hippocampal neurons. J Neurochem 2004; 90: 979-988.
51. Demar Jr JC, Ma K, Chang L, Bell JM, Rapoport SI. alpha-Linolenic acid does not contribute appreciably to docosahexaenoic acid within brain phospholipids of adult rats fed a diet enriched in docosahexaenoic acid. J Neurochem 2005; 94: 1063-1076.
52. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957; 226: 497-509.
53. Makrides M, Neumann MA, Byard RW, Simmer K, Gibson RA. Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-fed infants. Am J Clin Nutr 1994; 60: 189-194.
54. Bazinet RP, Rao JS, Chang L, Rapoport SI, Lee HJ. Chronic valproate does not alter the kinetics of docosahexaenoic acid within brain phospholipids of the unanesthetized rat. Psychopharmacology (Berlin) 2005; 182: 180-185.
55. Lahiri DK. An region upstream of the gene promoter for the beta-amyloid precursor protein interacts with proteins from nuclear extracts of the human brain and PC12 cells. Brain Res Mol Brain Res 1998; 58: 112-122.
56. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
57. Ghelardoni S, Tomita YA, Bell JM, Rapoport SI, Bosetti F. Chronic carbamazepine selectively downregulates cytosolic phospholipase A(2) expression and cyclooxygenase activity in rat brain. Biol Psychiatry 2004; 56: 248-254.
58. Rao JS, Rapoport SI, Bosetti F. Decrease in the AP-2 DNA-binding activity and in the protein expression of AP-2 alpha and AP-2 beta in frontal cortex of rats treated with lithium for 6 weeks. Neuropsychopharmacology 2005; 30: 2006-2013.
59. Carlezon Jr WA, Mague SD, Parow AM, Stoll AL, Cohen BM, Renshaw PF. Antidepressant-like effects of uridine and omega-3 fatty acids are potentiated by combined treatment in rats. Biol Psychiatry 2005; 57: 343-350.
60. Naliwaiko K, Araujo RL, da Fonseca RV, Castilho JC, Andreatini R, Bellissimo MI et al. Effects of fish oil on the central nervous system: a new potential antidepressant? Nutr Neurosci 2004; 7: 91-99.
61. Takenaka M, Kanada S, Hamazaki T, Watanabe S. Dietary supplementation with n-3 polyunsaturated fatty acids attenuates the depression of food-motivated behavior during zymosan-induced peritonitis. Biol Pharm Bull 2005; 28: 1291-1293.
62. Watanabe S, Kanada S, Takenaka M, Hamazaki T. Dietary n-3 fatty acids selectively attenuate LPS-induced behavioral depression in mice. Physiol Behav 2004; 81: 605-613.
63. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006; 311: 864-868.
64. Blendy JA. The role of CREB in depression and antidepressant treatment. Biol Psychiatry 2006; 59: 1144-1150.
65. Padma M, Das UN. Effect of cis-unsaturated fatty acids on the activity of protein kinases and protein phosphorylation in macrophage tumor (AK-5) cells in vitro. Prostaglandins Leukot Essent Fatty Acids 1999; 60: 55-63.
66. Mirnikjoo B, Brown SE, Kim HF, Marangell LB, Sweatt JD, Weeber EJ. Protein kinase inhibition by omega-3 fatty acids. J Biol Chem 2001; 276: 10888-10896.
67. Karege F, Schwald M, Papadimitriou P, Lachausse C, Cisse M. The cAMP-dependent protein kinase A and brain-derived neurotrophic factor expression in lymphoblast cells of bipolar affective disorder. J Affect Disord 2004; 79: 187-192.
68. Perez J, Tardito D, Racagni G, Smeraldi E, Zanardi R. cAMP signaling pathway in depressed patients with psychotic features. Mol Psychiatry 2002; 7: 208-212.
69. Tardito D, Mori S, Racagni G, Smeraldi E, Zanardi R, Perez J. Protein kinase A activity in platelets from patients with bipolar disorder. J Affect Disord 2003; 76: 249-253.
70. Chang A, Li PP, Warsh JJ. cAMP-Dependent protein kinase (PKA) subunit mRNA levels in postmortem brain from patients with bipolar affective disorder (BD). Brain Res Mol Brain Res 2003; 116: 27-37.
71. Chang A, Li PP, Warsh JJ. Altered cAMP-dependent protein kinase subunit immunolabeling in post-mortem brain from patients with bipolar affective disorder. J Neurochem 2003; 84: 781-791.
72. Rao JS, Bazinet RP, Rapoport SI, Lee HJ. Chronic administration of carbamazepine downregulates AP-2 DNA binding activity and AP-2a protein expression in rat frontal cortex. Biol Psychiatry, 23 June 2006 [Epub ahead of print].
73. Wang HY, Friedman E. Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biol Psychiatry 1996; 40: 568-575.
74. Dwivedi Y, Rizavi HS, Roberts RC, Conley RC, Tamminga CA, Pandey GN. Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. J Neurochem 2001; 77: 916-928.
75. Dwivedi Y, Rizavi HS, Conley RR, Pandey GN. ERK MAP kinase signaling in post-mortem brain of suicide subjects: differential regulation of upstream Raf kinases Raf-1 and B-Raf. Mol Psychiatry 2006; 11: 86-98.
76. Davis RJ. The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 1993; 268: 14553-14556.
77. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J 1995; 9: 726-735.
78. Einat H, Manji HK, Gould TD, Du J, Chen G. Possible involvement of the ERK signaling cascade in bipolar disorder: behavioral leads from the study of mutant mice. Drug News Perspect 2003; 16: 453-463.
79. Monteggia LM, Luikart B, Barrot M, Theobold D, Malkovska I, Nef S et al. Brain-derived neurotrophic factor conditional knock-outs show gender differences in depression-related behaviors. Biol Psychiatry, 11 May 2006 [Epub ahead of print].
80. Mercier G, Lennon AM, Renouf B, Dessouroux A, Ramauge M, Courtin F et al. MAP kinase activation by fluoxetine and its relation to gene expression in cultured rat astrocytes. J Mol Neurosci 2004; 24: 207-216.
81. Lin Z, Zhang PW, Zhu X, Melgari JM, Huff R, Spieldoch RL et al. Phosphatidylinositol 3-kinase, protein kinase C, and MEK1/2 kinase regulation of dopamine transporters (DAT) require N-terminal DAT phosphoacceptor sites. J Biol Chem 2003; 278: 20162-20170.
82. Moron JA, Zakharova I, Ferrer JV, Merrill GA, Hope B, Lafer EM et al. Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J Neurosci 2003; 23: 8480-8488.
83. Samuvel DJ, Jayanthi LD, Bhat NR, Ramamoorthy S. A role for p38 mitogen-activated protein kinase in the regulation of the serotonin transporter: evidence for distinct cellular mechanisms involved in transporter surface expression. J Neurosci 2005; 25: 29-41.
84. Kuperstein F, Yakubov E, Dinerman P, Gil S, Eylam R, Salem Jr N et al. Overexpression of dopamine receptor genes and their products in the postnatal rat brain following maternal n-3 fatty acid dietary deficiency. J Neurochem 2005; 95: 1550-1562.
85. Kodas E, Galineau L, Bodard S, Vancassel S, Guilloteau D, Besnard JC et al. Serotoninergic neurotransmission is affected by n-3 polyunsaturated fatty acids in the rat. J Neurochem 2004; 89: 695-702.
86. Akbar M, Calderon F, Wen Z, Kim HY. Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc Natl Acad Sci USA 2005; 102: 10858-10863.
87. Darios F, Davletov B. Omega-3 and omega-6 fatty acids stimulate cell membrane expansion by acting on syntaxin 3. Nature 2006; 440: 813-817.
88. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 2005; 115: 2774-2783.
89. Marcheselli VL, Hong S, Lukiw WJ, Tian XH, Gronert K, Musto A et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 2003; 278: 43807-43817.
90. Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004; 43: 633-645.